PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.